Equipped with advanced technology and a skilled team, Creative Biolabs offers premium Alphavirus VLP services, utilizing both Pichia pastoris and baculovirus expression systems. Our services include custom recombinant plasmid packaging, VLP purification, titer determination, and comprehensive in vitro and in vivo evaluations, ensuring top-quality solutions for vaccine research and gene therapy applications at competitive prices.
Alphaviruses, such as western equine encephalitis virus (WEEV), eastern equine encephalitis virus (EEEV), and Venezuelan equine encephalitis virus (VEEV), belong to the category of single-stranded positive-sense RNA-enveloped viruses. The envelope proteins of Alphavirus exhibit icosahedral symmetry, with E2 and E1 glycoproteins forming heterodimers that assemble into 80 trimers. These trimers play a crucial role in receptor interaction and mediating virus-cell membrane fusion. When Alphavirus serves as a vector for gene transfer, the Alphavirus replicon contains cis-acting sequences at both the 5ʹ and 3ʹ ends of the viral genome, as well as all non-structural protein genes. The foreign gene replaces the structural protein ORF, which is then transcribed by the provided helper RNA before being packaged into virus-like particles (VLPs). These replicons enter susceptible host cells and replicate using the viral RNA polymerase complex encoded within the replicons. Alphavirus VLPs closely resemble genuine viruses in appearance and immunogenicity but lack the ability to spread the virus. As a result, they have numerous applications in vaccine research and production.
Fig.1 Structure of Alphavirus VLPs.1
The Alphavirus VLPs from Creative Biolabs provide numerous benefits, including customized gene therapy capabilities and versatile applications in vaccine research and development, gene therapy, and various other fields. Figure 2 illustrates the construction of hACE2 with VEEV replicon particles (VEEV-VRP-hACE2), which is one of the Venezuelan equine encephalitis virus-like particles (VEEVLPs), composed of the VEEV-hACE2 replicon along with two helper RNAs, each expressing the structural protein separately. To generate the VEEVLPs, the hACE2 gene, fused with an S tag sequence, was inserted into a VEEV-TC83 infectious clone, replacing the natural viral capsid structural protein. The two helper RNAs had the VEEV genome, covering most of the nsP4 gene, removed, and a TAA stop codon was introduced at the 3' terminus of the nsP3 gene. Capsid and envelope genes were inserted and expressed independently.
Fig.2 Schematic illustration of VEEV-hACE2 replicon and helper RNA genomes and transduction of host cells with VEEVLPs.2
Creative Biolabs is dedicated to delivering top-notch Alphavirus VLP services worldwide. These VLPs are generated using two distinct expression systems: one based on the yeast Pichia pastoris and the other utilizing baculovirus (BEVS). We offer tailored services encompassing recombinant plasmid packaging for Alphavirus VLPs, along with purification and titer determination. Moreover, we provide a comprehensive approach that involves evaluating VLP protein expression and synthesis through western blotting, immunofluorescence indirect (IFI), and electron microscopy techniques in vitro, and conduct immunogenicity studies of Alphavirus VLPs in vivo upon request. For detailed information, please reach out to us and request a quote. We guarantee a response within 24 hours and will collaborate with you to devise the optimal strategy for your project.
Inquire About Our ServicesA: VEEVLPs are virus-like particles derived from the Venezuelan Equine Encephalitis Virus. They resemble the natural virus in structure and immunogenicity but lack the ability to replicate. These particles are primarily used in vaccine development, gene therapy, and research to safely mimic viral infection without the risk of spreading the actual virus.
A: VEEVLPs are generated by replacing the structural protein of the VEEV genome with a foreign gene, using helper RNAs to package the gene into virus-like particles. These are then produced using expression systems such as yeast or baculovirus, ensuring high-yield production for various research applications.
A: VEEVLPs offer significant advantages in gene therapy, including high transduction efficiency, the ability to target specific cells or tissues, and a lower risk of eliciting an immune response. These features make VEEVLPs a promising option for achieving more precise and effective gene delivery compared to traditional vectors.
A: VEEVLPs are widely used in vaccine research, gene therapy, and the study of viral infections. Their ability to mimic natural viral infections without spreading makes them valuable tools in developing new therapies and understanding immune responses to viruses.
A: VEEVLPs are used to deliver antigens in a way that mimics a natural infection, thereby eliciting a robust immune response. This property makes them highly effective in preclinical vaccine development, where they help in studying immune responses and optimizing vaccine formulations.
A: Quality control for VEEVLPs includes various assessments such as western blotting, immunofluorescence indirect (IFI), and electron microscopy to ensure proper protein expression and particle formation. These rigorous checks guarantee that the VLPs produced are of high quality and suitable for research.
lphavirus replicon particles (VRPs) were employed in this study to deliver a vaccine targeting the SARS-CoV-2 Omicron variant. The VRPs were constructed using a Venezuelan equine encephalitis virus (VEEV) replicon encoding the prefusion-stabilized spike protein of the Omicron variant. These particles are capable of self-replicating within the host cells, enhancing the expression of the spike protein and activating an immune response. The experimental results demonstrated that VRP-S-2P, when administered to mice and hamsters, induced strong antibody responses and provided robust protection against the Omicron variant. Specifically, intraperitoneal (IP) and intramuscular (IM) routes of administration were most effective, significantly reducing viral loads in the lungs and preventing lung lesions in challenged animals. These findings suggest that VRPs are a potent platform for vaccine development, particularly against rapidly evolving viral variants.
Fig.3 IIF and WB Detection results of SARS-CoV-2 spike protein following transfection with VEEV-S-2P and infection with VRP-S-2P.3
| Cat. No | Product Name | Promoter |
|---|---|---|
| GTVCR-WQ79MR | IVTScrip™ pT7-VEE-mRNA-Anti-AMHR2, 3C23K Vector | T7 |
| GTVCR-WQ82MR | IVTScrip™ pSP6-VEE-mRNA-Anti-AMHR2, 3C23K Vector | SP6 |
| GTVCR-WQ83MR | IVTScrip™ pT7-VEE-mRNA-Anti-PDGFRA, 3G3 Vector | T7 |
| GTVCR-WQ86MR | IVTScrip™ pSP6-VEE-mRNA-Anti-PDGFRA, 3G3 Vector | SP6 |
| GTVCR-WQ87MR | IVTScrip™ pT7-VEE-mRNA-Anti-SELP, 42-89-glycoprotein Vector | T7 |
| Cat. No | Product Name | Type |
|---|---|---|
| GTTS-WQ45MR | IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) | Antibody |
| GTTS-WQ46MR | IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) | Antibody |
| GTTS-WQ47MR | IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) | Antibody |
| GTTS-WQ48MR | IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) | Antibody |
| GTTS-WQ49MR | IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) | Antibody |
References
